isoxazoles has been researched along with Lymphoma, Large B-Cell, Diffuse in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, JS; Chang, KC; Chen, LT; Chen, TY; Cheng, AL; Kuo, SH; Lin, HY; Lin, SF; Shih, NY; Tsai, HJ | 1 |
| Fowler, N; Hagemeister, F; Knickerbocker, J; Kwak, L; Nastoupil, L; Oki, Y; Romaguera, J; Samaniego, F; Westin, J; Younes, A | 1 |
1 trial(s) available for isoxazoles and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma.
Topics: Antineoplastic Agents; Diarrhea; Drug Administration Schedule; Edema; Fatigue; Female; Gene Expression; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Recurrence; Remission Induction; Resorcinols; Retrospective Studies; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2015 |
1 other study(ies) available for isoxazoles and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.
Topics: Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Caspase 3; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromosome Aberrations; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Disease Models, Animal; Down-Regulation; Enzyme Activation; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lymphoma, Large B-Cell, Diffuse; Male; Mice; Mitochondria; Neoplasm Grading; NF-kappa B; Resorcinols; Signal Transduction; Translocation, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |